Skip to main content

Table 12 Factors associated with MetS according to NCEP-ATP III criteria, results from univariate and multivariate logistic regression, (CMD- set, N = 476)

From: Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

Univariate logistic regression

Effect, Visit 1

Odds Ratio

95% CI

p-Value

Age

1.03

1.02 to 1.05

<.0001

Time since first symptoms (years)

1.02

1.00 to 1.04

0.0399

Concomitant somatic disease: Y vs. N

4.83

3.09 to 7.53

<.0001

Non-psychiatric co-medication: Y vs. N

3.38

2.15 to 5.31

<.0001

Smoking status: Y vs. N

0.61

0.42 to 0.89

0.0107

CRP ≥3 mg/L vs. normal value

1.68

1.11 to 2.56

0.0151

Prev-Comb vs. Prev-None

3.56

1.89 to 6.70

<.0001

Prev-Olz vs. Prev-None

2.91

1.40 to 6.05

0.0043

Prev-Atyp vs. Prev-None

3.27

1.72 to 6.24

0.0003

Prev-Quet vs. Prev-None

3.74

1.73 to 8.09

0.0008

Prev-Risp vs. Prev-None

2.62

1.27 to 5.39

0.0091

Prev-Typ vs. Prev-None

3.07

1.59 to 5.91

0.0008

Effect, Visit 2

Odds Ratio

95% CI

p-Value

Age

1.02

1.01 to 1.04

0.0042

Time since first symptoms (years)

1.03

1.01 to 1.04

0.0059

Concomitant somatic disease: Y vs. N No

3.98

2.57 to 6.19

<.0001

Non-psychiatric co-medication: Y vs. N No

2.67

1.71 to 4.16

<.0001

CRP ≥3 mg/L vs. normal value

2.36

1.58 to 3.51

<.0001

Prev-Comb vs. Prev-None

2.63

1.44 to 4.81

0.0017

Prev-Olz vs. Prev-None

2.63

1.30 to 5.33

0.0071

Prev-Atyp vs. Prev-None

2.07

1.11 to 3.85

0.0216

Prev-Quet vs. Prev-None

2.38

1.13 to 5.04

0.0232

Prev-Risp vs. Prev-None

2.16

1.08 to 4.33

0.0292

Prev-Typ vs. Prev-None

2.29

1.22 to 4.29

0.0098

Multivariate logistic regression

Effect, Visit 1

Odds Ratio

95% CI

p-Value

Concomitant somatic disease: Y vs. N

4.09

2.37 to 7.06

<.0001

Smoking status: Y vs. N

0.53

0.32 to 0.86

0.0098

Effect, Visit 2

Odds Ratio

95% CI

p-Value

CRP ≥3 mg/L vs. normal value

2.00

1.22 to 3.30

0.0062

Non-psychiatric co-medication: Y vs. N No:

1.98

0.98 to 4.04

0.0588

Concomitant somatic disease: Y vs. N No

1.83

0.93 to 3.61

0.0796

Sex: female vs. male

0.56

0.34 to 0.91

0.0185

Smoking status at visit 2: Y vs. N

0.60

0.37 to 1.00

0.0488

  1. Abbreviations: CI = confidence interval; CMD = complete metabolic data; CRP = ; C-reactive protein; MetS = metabolic syndrome; N = No; NCEP-ATP III = National Cholesterol Education Program, Adult Treatment Panel 3rd report; New-AP = new antipsychotic treatment cohort; Y = Yes
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us